22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- 29th Shandong-Taiwan Economic and Trade Fair to facilitate cross-Strait talent recognition
- World's highest bridge passes crucial load test
- Nobel laureate partners with Shanghai Henlius Biotech for immunotherapy clinical trials
- Beluga whales witness 'Deep Sea Certification' wedding in Heilongjiang
- Anwen township hosts hundred-meter-long banquet for mutton festival
- China implements measures to boost graduates' job search
